Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 13, Number 7—July 2007

Research

Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci

Marion A. Kainer*Comments to Author , Rose A. Devasia*†, Timothy F. Jones*, Bryan P. Simmons‡, Kelley Melton‡, Susan Chow‡, Joyce Broyles‡, Kelly L. Moore*, Allen S. Craig*, and William Schaffner§
Author affiliations: *Tennessee Department of Health, Nashville, Tennessee, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Methodist University Hospital, Memphis, Tennessee, USA; §Vanderbilt University School of Medicine, Nashville, Tennessee, USA;

Main Article

Figure 4

Linezolid (LZD) usage during 2001–2005 at hospital A, Tennessee. Use of oral and intravenous (IV) formulations is shown in defined daily doses (DDD)/1,000 patient days. Data for 2001 and 2005 do not include all 12 months (2001 includes data from October through December; 2005 includes data from January through February). ICU, intensive care unit.

Figure 4. Linezolid (LZD) usage during 2001–2005 at hospital A, Tennessee. Use of oral and intravenous (IV) formulations is shown in defined daily doses (DDD)/1,000 patient days. Data for 2001 and 2005 do not include all 12 months (2001 includes data from October through December; 2005 includes data from January through February). ICU, intensive care unit.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO